Abstract
Numerous allergens have been cloned and produced by the use of recombinant DNA technology. In several cases recombinant variants with reduced IgE-reactivity have also been developed as candidates for allergen specific immunotherapy. Only very few of these proteins have as yet been tested in the clinic, and the major focus has been on birch and grass pollen, two of the most common causes of IgE-mediated allergic disease. This article serves to justify the rational for using recombinant products and reviews the progress that has been made to date with their clinical assessment.
MeSH terms
-
Allergens / administration & dosage
-
Allergens / immunology
-
Allergens / therapeutic use
-
Animals
-
Antigens, Plant / administration & dosage
-
Antigens, Plant / immunology
-
Antigens, Plant / therapeutic use
-
Cats
-
Desensitization, Immunologic / methods*
-
Humans
-
Hypersensitivity / immunology*
-
Hypersensitivity / therapy*
-
Immune Tolerance*
-
Immunoglobulin E / immunology
-
Pollen / immunology
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / immunology
-
Recombinant Proteins / therapeutic use
-
Rhinitis, Allergic, Seasonal / immunology
-
Rhinitis, Allergic, Seasonal / therapy
Substances
-
Allergens
-
Antigens, Plant
-
Recombinant Proteins
-
Immunoglobulin E